Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial

Most guidelines recommend long-acting bronchodilators over short-acting bronchodilators for patients with chronic obstructive pulmonary disease (COPD). The available evidence for the guidelines was based on dry powder or pressurized metered dose inhalers, but not nebulizations. Nevertheless, there is considerable, poorly evidenced based, use of short acting nebulized bronchodilators.

Source: Respiratory Medicine - July 2, 2020 Category: Respiratory Medicine Authors: Wouter H. van Geffen, Orestes A. Carpaij, Lotte F. Westbroek, Dianne Seigers, Alice Niemeijer, Judith M. Vonk, Huib A.M. Kerstjens Source Type: research